<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798459</url>
  </required_header>
  <id_info>
    <org_study_id>0009-12-SHA</org_study_id>
    <nct_id>NCT01798459</nct_id>
  </id_info>
  <brief_title>The Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder.</brief_title>
  <official_title>A Double Blind Randomized Crossover Study of the Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the effect of methylphenidate on state anxiety in
      children with attention deficit hyperactivity disorder.

      Patient population: 30 children diagnosed with attention deficit hyperactivity disorder. The
      subjects will be of all racial, ethnical and gender categories, ranging from 8 to 18 years of
      age.

      Structure: the study is a randomized double blind crossover study. The subjects will complete
      a continuous performance test, the cambridge neuropsychological test automated Battery,
      before and after given methylphenidate or placebo on the first day of the study. On the
      second day of the study, the subjects will receive either methylphenidate or placebo based on
      what was given on the first day of the study and they will complete the same task.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>State anxiety</measure>
    <time_frame>1 year</time_frame>
    <description>State anxiety will be measured by the Spielberger's state anxiety inventory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>1 year</time_frame>
    <description>Cognitive function will be measured by the cambridge neuropsychological test automated battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's perspective</measure>
    <time_frame>1 year</time_frame>
    <description>Patient's perspective will be measured by questionnaires assessing treatment adherence issues and patient's view regarding the use of placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Methylphenidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylphenidate 0.3 mg/kg per os is given before performing a continuous performance test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is given before performing a continuous performance test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <arm_group_label>Methylphenidate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Attention deficit and hyperactivity disorder

          -  Children aged 8-18 years

        Exclusion Criteria:

          -  Pervasive developmental disorder

          -  Schizophrenia

          -  Bipolar disorder

          -  Current depressive episode

          -  Current Anxiety disorder

          -  Drug use during the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya Kritchman Lupo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvata Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maya Kritchman-Lupo, MD</last_name>
    <phone>972-9-7478644</phone>
    <email>maiakr@clalit.org.il; mayakri@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuval Bloch, MD</last_name>
    <phone>972-9-7478510</phone>
    <email>yuvalbl@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shalvata</name>
      <address>
        <city>Hod-hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Kritchman-Lupo, MD</last_name>
      <phone>972-9-7478644</phone>
      <email>maiakr@clalit.org.il; mayakri@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2013</study_first_posted>
  <last_update_submitted>March 20, 2015</last_update_submitted>
  <last_update_submitted_qc>March 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shalvata Mental Health Center</investigator_affiliation>
    <investigator_full_name>Maya Kritchman Lupo</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Placebo</keyword>
  <keyword>State anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

